‘Risk share’ with us, say CCGs
December 6, 2012Sales and Marketing CCGs, NHS, Pharmafocus, Prescriber, pharma
Pharma companies have been urged to “put your head on the block” by coming up with risk-sharing funding plans for …
uniQure appoints Basilea’s chief commercial officer
December 6, 2012Manufacturing and Production, Research and Development, Sales and Marketing Basilea, uniQure
Dutch human gene therapy firm uniQure has appointed Hans Christian Rohde as chief commercial officer. Rohde joins uniQure from Basilea …
ImmunoCellular appoints Andrew Gengos as chief executive
December 5, 2012Manufacturing and Production, Research and Development, Sales and Marketing Gengos, ImmunoCellular
Clinical stage firm ImmunoCellular Therapeutics has announced the appointment of Andrew Gengos as president and chief executive and member of …
New boost for drug candidates
December 5, 2012Research and Development, Sales and Marketing Bayer, EFPIA, K4DD, Leiden
A new project is trying to increase the hit rates of successful drug candidates by improving the way they are …
Trajenta may reduce stroke damage
December 4, 2012Research and Development, Sales and Marketing Boehringer, EMA, Trajenta, diabetes, linagliptin
Boehringer Ingelheim’s diabetes drug Trajenta could one day be used to minimise the effects of brain damage following stroke. Scientists …
Excipient certification project moves forward
December 4, 2012Manufacturing and Production DEG, EXCiPACT, GDP, GMP
The EXCiPACT certification scheme for pharmaceutical excipients has taken a step closer to fruition with agreements now in place with …
R&D costs rise ten-fold
December 4, 2012Research and Development, Sales and Marketing OHE, R&D, research and development
Research by the Office of Health Economics (OHE) think tank shows that the cost of pharma R&D has risen ten-fold …
NHS ‘entering treacherous waters’
December 3, 2012Sales and Marketing Ham, NHS, coalition, king's fund, reforms
A leading think tank has marked the coalition government’s health policy with what amounts to a C+ in its mid-term …
J&J’s Alex Gorsky to be chairman and chief executive
December 3, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Johnson & Johnson has has elected its chief executive Alex Gorsky to be its chairman of the Board of directors. …
Pharmacos ink green manufacturing pact with EU academics
December 3, 2012Manufacturing and Production Bayer, EU, Pharmacos, Sanofi
A group of top pharma multinationals have set up a public-private partnership dedicated to the development of manufacturing sustainable pharmaceuticals …
Janssen eases HIV patent burden
December 3, 2012Sales and Marketing AIDS, Janssen, Prezista, darunavir
In a move which should appeal to public health campaigners, Janssen has declared that it will not enforce patents for …
Help CCGs help you, pharma told
November 30, 2012Medical Communications, Sales and Marketing CCGs, JSNA, NHS, pharma
Pharma companies have a big opportunity to take advantage of the changes in the structure of the NHS, according to …
Ranbaxy suspends atorvastatin manufacturing after recall
November 30, 2012Manufacturing and Production FDA, Ranbaxy, atorvastatin, recall
Ranbaxy Laboratories has called a halt to manufacturing its generic atorvastatin product until it can get to the bottom of …
New chief executive for Cipla
November 30, 2012Manufacturing and Production, Research and Development, Sales and Marketing Cipla, Subhanu Saxena
Indian pharma firm Cipla has announced the appointment of Novartis’ Subhanu Saxena as its chief executive. Saxena joins Cipla in …
NICE: ‘lot of work’ to do on VBP
November 30, 2012Medical Communications, Sales and Marketing Boysen, NHS, NICE, QALY, VBP
NICE is still working out what its role with the new NHS Commissioning Board will be, with other key issues …
Novartis R&D warning
November 29, 2012Research and Development, Sales and Marketing NHS, Novartis. R&D, trials
Novartis has hit out at what it sees as the high cost of UK clinical trials, warning that business will …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
Genzyme appoints new GM for UK and Ireland
November 29, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brendan Martin, Genzyme
Genzyme has announced the appointment of Brendan Martin as general manager for UK and Ireland. Martin will be responsible for …
Survey: pharma losing $564 billion each year
November 28, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cap Gemini, Health Prize, pharma
Pharma companies are losing $564 billion each year – more than half the industry’s $956 billion revenue worldwide last year …
Another indication for Humira
November 28, 2012Sales and Marketing Abbott, Crohn's, EU, Humira
Abbott’s Humira has received its ninth indication in Europe with approval to treat youngsters suffering from the inflammatory bowel disease …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
